Warm antibody hemolytic anemia
Other Names for this Disease
- Warm-reacting-antibody hemolytic anemia
- Warm antibody autoimmune hemolytic anemia
- Warm antibody AIHA
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
autoimmune hemolytic anemia. It is defined by the presence of autoantibodies that attach to and destroy red blood cells at temperatures equal to or greater than normal body temperature. The disease is characterized by symptoms related to anemia, including fatigue, difficulty breathing, jaundice and dark urine. In severe disease, fever, chest pain, syncope or heart failure may occur. Hemolysis (the breakdown of red blood cells) occurs mainly in the spleen, so mild splenomegaly is relatively common. Treatment typically involves a corticosteroid like prednisone. In cases that don't respond to treatment, splenectomy may be considered. Chronic and severe disease may be treated with Rituximab or immunosuppressive medications. Warm antibody hemolytic anemia is the most common form of
Last updated: 12/19/2012
- Lichtin AE. Autoimmune Hemolytic Anemia. Merck Manual. 2016; http://www.merckmanuals.com/home/blood-disorders/anemia/autoimmune-hemolytic-anemia.
- Michel M. Autoimmune hemolytic anemia, warm type. Orphanet. August 2012; http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=90033. Accessed 12/19/2012.
- The Merck Manuals Online Medical Library provides information on this condition for patients and caregivers.
- The National Heart, Lung, and Blood Institute (NHLBI) has information on this topic. NHLBI is part of the National Institutes of Health and supports research, training, and education for the prevention and treatment of heart, lung, and blood diseases.
- The National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.